Study compares bivalirudin and heparin in patients undergoing percutaneous coronary intervention
Bivalirudin offers a slightly better coagulation function and safety profile compared to heparin in patients undergoing percutaneous coronary intervention (PCI), while both drugs are equally effective in preventing postoperative cardiovascular events, according to a study.
The research included 42 patients with coronary heart disease treated with bivalirudin or heparin during the perioperative period. Key metrics such as coagulation indicators, cardiac and organ function markers, and adverse events were monitored for up to 12 months.
The bivalirudin group had significantly lower activated clotting time, D-dimer, and prothrombin time compared to the heparin group. In addition, bivalirudin was associated with lower levels of Creatine Kinase-MB and NT-proBNP, markers of cardiac stress. Both groups showed improved Thrombolysis In Myocardial Infarction flow grades post-PCI, and no severe cardiovascular or cerebrovascular events were reported in either group.
Reference
Wang Y, Ren X, Song Z, et al. Comparison of the effects on coagulation function and safety of bivalirudin and heparin in patients undergoing percutaneous coronary intervention: A randomized trial. Medicine (Baltimore). 2024;103(48):e40731. doi: 10.1097/MD.0000000000040731. PMID: 39612389; PMCID: PMC11608685.
